Stockrabit · Analysts
Questions across 6 calls

Mehul Panjuani

40 Cents

Neuland Laboratories Limited

Laurus Labs Limited

Analysts/Institutional Investor Meet/Con. Call Updates Laurus Labs Limited has informed the Exchange about Transcript · 2026-04-30
My first question is about CDMO pipeline. Out of the expanding CDMO pipeline, how much is expected to convert into commercial revenues in FY '27? And what is the revenue visibility from late-stage molecules?
Right, sir. Sir, my second question is about the margins. How sustainable are the current 29% EBITDA margins? And how much is driven by mix versus temporary operating leverage?

BLS International Services Limited

Thermax Limited

Natco Pharma Limited